2019年冠状病毒病(COVID-19)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
食品药品监督管理局
授权
2019-20冠状病毒爆发
诊断试验
大流行
医学
病毒学
重症监护医学
风险分析(工程)
计算机科学
计算机安全
病理
传染病(医学专业)
儿科
疾病
爆发
作者
Meral Yüce,Elif Filiztekin,Korin Ozkaya
标识
DOI:10.1016/j.bios.2020.112752
摘要
A fast and accurate self-testing tool for COVID-19 diagnosis has become a prerequisite to comprehend the exact number of cases worldwide and to take medical and governmental actions accordingly. SARS-CoV-2 (formerly, 2019-nCoV) infection was first reported in Wuhan (China) in December 2019, and then it has rapidly spread around the world, causing ~ 14 million active cases with ~ 582,000 deaths as of July 2020. The diagnosis tools available so far have been based on a) viral gene detection, b) human antibody detection, and c) viral antigen detection, among which the viral gene detection by RT-PCR has been found as the most reliable technique. In this report, the current SARS-CoV-2 detection kits, exclusively the ones that were issued an “Emergency Use Authorization” from the U.S. Food and Drug Administration, were discussed. The key structural components of the virus were presented to provide the audience with an understanding of the scientific principles behind the testing tools. The methods that are still in the early research state were also reviewed in a subsection based on the reports available so far. • The structural biomarkers of SARS-CoV-2 are described. • Viral gene, antigen, and antibody-based detection methods are discussed. • Emergency Use Authorization-issued commercial test kits are explained. • The methods at early research-stage are summarized.
科研通智能强力驱动
Strongly Powered by AbleSci AI